For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

For the quarter ended December 2025, Veris Residential (VRE) reported revenue of $71.31 million, up 4.7% over the same period last year. EPS came in at $0.19, compared to -$0.13 in the year-ago quarter.The reported revenue represents a surprise of +1.34% over the Zacks Consensus Estimate of $70.37 million. With the consensus EPS estimate being $0.16, the EPS surprise was +16.35%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Core Insights - Zoom Video Communications (ZM) is expected to report fourth-quarter fiscal 2026 results on February 25, with projected revenues between $1.23 billion and $1.235 billion, indicating a year-over-year growth of 4.08% [1] - Non-GAAP earnings per share are anticipated to be in the range of $1.48 to $1.49, reflecting a year-over-year increase of 4.96% [2] - The company has maintained a steady consensus estimate for earnings at $1.48 per share, with an average surprise of 8.9% over the last four quarters [2] Revenue and Earnings Expectations - The Zacks Consensus Estimate for revenue is currently pegged at $1.23 billion, aligning with the company's expectations [1] - The Earnings ESP for ZM is 0.00%, and it currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook for earnings performance [3] Business Environment and Growth Factors - Zoom is navigating a mature growth phase, leading to cautious optimism among investors [4] - The launch of AI Companion 3.0 in December 2025 and new agentic tools are expected to drive enterprise upsell activity [5] - Strategic partnerships with Oracle and NVIDIA are seen as potential growth levers, enhancing customer engagement and enterprise AI capabilities [6] Competitive Landscape and Challenges - The competitive environment remains challenging, with Microsoft Teams, RingCentral, and Cisco Webex aggressively targeting enterprise collaboration budgets [7] - ZM's net dollar expansion rate is at 98%, but online segment growth is only 2%, indicating constraints in expanding within the existing customer base [7] - The projected non-GAAP operating margin for Q4 is 38.9%, slightly down from 41.2% in the previous quarter, suggesting near-term profitability pressure [7] Investor Sentiment - Given the modest growth trajectory and limited near-term catalysts, investors may consider holding existing positions or waiting for a more favorable entry point before increasing exposure [8][9]

Key Takeaways Roche's FDA filing for giredestrant in ER-positive breast cancer accepted, with a Dec. 18, 2026 action date.RHHBY's phase III evERA study showed a 44% lower progression risk in ITT and 62% in ESR1-mutated patients.Roche plans more filings as giredestrant advances across five phase III studies in multiple settings.Roche (RHHBY) announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment o ...

Core Insights - Microsoft reported strong fiscal second-quarter 2026 earnings, with revenues of $81.3 billion, a 17% year-over-year increase, and operating income rising 21% to $38.3 billion, but concerns over capital expenditure led to a nearly 5% drop in stock price after hours [1][2] Financial Performance - For the quarter ended December 31, 2025, Microsoft achieved revenues of $81.3 billion, a 17% increase year-over-year, and operating income of $38.3 billion, up 21% [2] - Non-GAAP earnings per share were reported at $4.14, indicating solid performance by conventional measures [2] Capital Expenditure - Capital expenditures and finance leases for the quarter reached $37.5 billion, a significant 66% increase from the previous year, exceeding market expectations [3] - The first half of fiscal 2026 saw total capital expenditures of $72.4 billion, suggesting an annual infrastructure spending trajectory of approximately $100 billion [3] - Two-thirds of the second-quarter capital expenditure was allocated to short-lived assets, primarily GPUs and CPUs, while the remainder was directed towards long-lived infrastructure [3] Market Dynamics - Microsoft acknowledged that customer demand continues to exceed supply, with guidance indicating a slight decline in operating margins for the fiscal third quarter [4] - The cost of goods sold is expected to grow by 22% to 23%, and capital expenditure is projected to decrease sequentially in the third quarter [4] Backlog and Future Revenue Potential - The commercial remaining performance obligation stands at $625 billion, more than doubling year-over-year, with 45% linked to OpenAI commitments, indicating future revenue potential but also sustained infrastructure obligations [5] - Rising R&D costs contribute to stock sensitivity regarding the pace of AI infrastructure buildout relative to revenue conversion [5] Industry Comparisons - Microsoft is not alone in facing capital expenditure pressures; Amazon has guided for approximately $200 billion in capital expenditures for 2026, while Alphabet projects $175 billion to $185 billion, both companies experiencing similar investor scrutiny regarding infrastructure-heavy AI investments [6] Stock Performance and Valuation - Microsoft shares have declined by 21.2% over the past six months, outperforming the Zacks Computer – Software industry decline of 24.5% but underperforming the Zacks Computer and Technology sector's return of 10.6% [7] - The stock is currently trading at a forward 12-month Price/Sales ratio of 8.25X, compared to the industry's 6.92X, indicating a relatively higher valuation [10] - The Zacks Consensus Estimate for fiscal 2026 earnings is $16.97 per share, reflecting an 8.4% increase over the past 30 days and a year-over-year growth of 24.41% [13]

Key Takeaways United Airlines ordered 300 GEnx engines to power new Boeing 787 Dreamliners. The deal lifts GE Aerospace's GEnx backlog to nearly 1,800 engines plus spares. UAL's fleet commonality with GEnx engines aims to cut costs and support global expansion.United Airlines (UAL) strengthened its long-term partnership with GE Aerospace (GE) by selecting 300 GEnx engines to power its new Boeing 787 Dreamliners. This order will expand UAL’s 787 fleet to more than 200 GEnx-powered aircraft and make it the l ...

Core Insights - Adobe shares closed at $258.61, approximately 43% below the 52-week high of $453.26 reached on March 5, 2025, with a 41.8% decline over the past 12 months, underperforming the broader tech sector and software industry [1][7] - The company's future growth is heavily reliant on its AI initiatives, targeting an annualized recurring revenue growth of 10.2% for fiscal 2026, driven by an innovative AI-powered portfolio and expanding enterprise adoption [2][7] Performance Comparison - Adobe's AI-related revenues are significantly lower than competitors like Microsoft, Alphabet, and Salesforce, which have seen substantial growth in their AI offerings [3] - Over the past 12 months, Adobe has underperformed compared to Alphabet, which saw a 75.8% increase, while Microsoft and Salesforce experienced declines of 1.6% and 39.9%, respectively [4] Revenue and Earnings Forecast - For the first quarter of fiscal 2026, Adobe anticipates revenues between $6.25 billion and $6.3 billion, with non-GAAP earnings expected to be $5.85-$5.90 per share [10] - The Zacks Consensus Estimate for fiscal first-quarter earnings is $5.88 per share, indicating a 15.8% growth year-over-year, while revenues are expected to grow by 10% to $6.28 billion [11] - For fiscal 2026, Adobe expects revenues between $25.9 billion and $26.1 billion, with non-GAAP earnings projected between $23.30 and $23.50 per share, reflecting a 9.5% revenue growth and 12.1% earnings growth from fiscal 2025 [12] Strategic Initiatives - Adobe is experiencing strong demand for its AI-powered products, including Creative Cloud Pro and Acrobat, and is enhancing user experiences through new AI features [8][9] - The company is expanding its partner base and integrating with leading AI ecosystems, which is expected to bolster its market position [9] Valuation and Investment Outlook - Adobe holds a Value Score of B, indicating a potentially attractive valuation for investors [13] - The current Zacks Rank for Adobe is 3 (Hold), suggesting that investors may want to wait for a more favorable entry point [17]

Key Takeaways CRMD's Q4 results are expected to reflect strong DefenCath sales and incremental Melinta contribution.CorMedix expects 2026 revenues of $300-$320M, with DefenCath sales weighted to early 2026.CRMD's preliminary Q4 sales of about $127M reflect DefenCath momentum and Melinta contributions.We expect investors to focus on the sales performance of CorMedix’s (CRMD) lead product, DefenCath (taurolidine plus heparin), when the company reports fourth-quarter and full-year 2025 results. The Zacks Conse ...

Key Takeaways Q4 Earnings Season Continues This Week: DPZ, BBBY & HIMS TodayNVIDIA Reports Wednesday After the Close, Expecting 70.8% Earnings GrowthPPI Caps Another Big Week of Economic DataMonday, February 23rd, 2026After a very eventful week for economic data and amount of Q4 earnings reports, we cool off some to stat a new trading week. We cap off “Mag 7” earnings with Wednesday afternoon’s NVIDIA (NVDA) Q4 report, and save our biggest economic news — January Producer Price Index (PPI), the wholesale si ...

Key Takeaways ANI Pharmaceuticals reports Q4 2025 earnings Feb. 27, with sales seen at $233M and EPS at $1.99.ANIP's Cortrophin Gel sales are expected at $114M, driven by 88% year-over-year growth.ANIP trades at 1.98x P/S, below the industry's 2.50x, with growth led by rare disease drugs.ANI Pharmaceuticals (ANIP) is set to report fourth-quarter and full-year 2025 earningson Feb. 27, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $233 million and $1.9 ...